FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975794106> ?p ?o ?g. }

• W1975794106 endingPage "147" @default.
• W1975794106 startingPage "142" @default.
• W1975794106 abstract "Adjuvant 5-fluorouracil-based chemoradiotherapy has been shown to improve the prognosis of gastric cancer. To optimize these results, in the present study oxaliplatin and capecitabine were used instead of 5-fluorouracil. We sought to determine the maximum tolerated dose and the dose-limiting toxicities (DLT) of these drugs in combination with intensity-modulated radiotherapy.Patients with resected adenocarcinoma of the stomach or the gastroesophageal junction were included. They received two cycles of induction chemotherapy (oxaliplatin and capecitabine [XelOx] regimen). Using standard Phase I methodology, patients received 45 Gy in 1.8-Gy fractions either in combination with capecitabine 825 mg m(-1) twice a day (Dose Level [DL] I) or capecitabine in combination with weekly oxaliplatin 40 or 50 mg m(-1) (DL II and III). After the completion of chemoradiation, two additional cycles of XelOx were scheduled.A total of 32 patients were recruited. Only 1 of 6 patients evaluable on DL I had DLT. Of the first 6 patients on DL II, 1 patient experienced DLT, and 3 of the remaining patients had Grade 3 toxicity. Therefore, DL II was defined as the maximum tolerated dose and a total of 20 patients were treated at this DL. The most frequently observed toxicities (Common Toxicity Criteria Grades 1, 2 and 3) were, respectively, leukocytopenia in 5, 5, and 4 patients; nausea in 3, 7, and 3; and diarrhea in 4, 0, and 1.In summary, capecitabine 825 mg m(-1) twice a day (Days 1-33) and weekly oxaliplatin 40 mg m(-1) was safe and tolerable in combination with intensity-modulated radiotherapy. Furthermore, four cycles of XelOx could be applied before and after chemoradiotherapy in two thirds of the patients." @default.
• W1975794106 created "2016-06-24" @default.
• W1975794106 creator A5010375570 @default.
• W1975794106 creator A5011887107 @default.
• W1975794106 creator A5015781558 @default.
• W1975794106 creator A5018229437 @default.
• W1975794106 creator A5023873669 @default.
• W1975794106 creator A5035964802 @default.
• W1975794106 creator A5052177007 @default.
• W1975794106 creator A5054393645 @default.
• W1975794106 creator A5075238372 @default.
• W1975794106 creator A5075338963 @default.
• W1975794106 creator A5086590565 @default.
• W1975794106 date "2009-01-01" @default.
• W1975794106 modified "2023-10-18" @default.
• W1975794106 title "Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial" @default.
• W1975794106 cites W1748728040 @default.
• W1975794106 cites W1990945921 @default.
• W1975794106 cites W2007965665 @default.
• W1975794106 cites W2012579585 @default.
• W1975794106 cites W2024289936 @default.
• W1975794106 cites W2026986976 @default.
• W1975794106 cites W2046311020 @default.
• W1975794106 cites W2061895058 @default.
• W1975794106 cites W2061953092 @default.
• W1975794106 cites W2077303015 @default.
• W1975794106 cites W2083582547 @default.
• W1975794106 cites W2087850501 @default.
• W1975794106 cites W2101382529 @default.
• W1975794106 cites W2115072149 @default.
• W1975794106 cites W2128328462 @default.
• W1975794106 cites W2130647939 @default.
• W1975794106 cites W2137730077 @default.
• W1975794106 cites W2141363209 @default.
• W1975794106 cites W2146266646 @default.
• W1975794106 cites W2150983705 @default.
• W1975794106 cites W2154773141 @default.
• W1975794106 cites W2171531063 @default.
• W1975794106 cites W2275248879 @default.
• W1975794106 cites W308129017 @default.
• W1975794106 doi "https://doi.org/10.1016/j.ijrobp.2008.04.033" @default.
• W1975794106 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18539404" @default.
• W1975794106 hasPublicationYear "2009" @default.
• W1975794106 type Work @default.
• W1975794106 sameAs 1975794106 @default.
• W1975794106 citedByCount "18" @default.
• W1975794106 countsByYear W19757941062012 @default.
• W1975794106 countsByYear W19757941062013 @default.
• W1975794106 countsByYear W19757941062014 @default.
• W1975794106 countsByYear W19757941062015 @default.
• W1975794106 countsByYear W19757941062016 @default.
• W1975794106 crossrefType "journal-article" @default.
• W1975794106 hasAuthorship W1975794106A5010375570 @default.
• W1975794106 hasAuthorship W1975794106A5011887107 @default.
• W1975794106 hasAuthorship W1975794106A5015781558 @default.
• W1975794106 hasAuthorship W1975794106A5018229437 @default.
• W1975794106 hasAuthorship W1975794106A5023873669 @default.
• W1975794106 hasAuthorship W1975794106A5035964802 @default.
• W1975794106 hasAuthorship W1975794106A5052177007 @default.
• W1975794106 hasAuthorship W1975794106A5054393645 @default.
• W1975794106 hasAuthorship W1975794106A5075238372 @default.
• W1975794106 hasAuthorship W1975794106A5075338963 @default.
• W1975794106 hasAuthorship W1975794106A5086590565 @default.
• W1975794106 hasConcept C121608353 @default.
• W1975794106 hasConcept C126322002 @default.
• W1975794106 hasConcept C141071460 @default.
• W1975794106 hasConcept C143998085 @default.
• W1975794106 hasConcept C2776694085 @default.
• W1975794106 hasConcept C2777909004 @default.
• W1975794106 hasConcept C2778424827 @default.
• W1975794106 hasConcept C2778496288 @default.
• W1975794106 hasConcept C2780456651 @default.
• W1975794106 hasConcept C2780580376 @default.
• W1975794106 hasConcept C2780962732 @default.
• W1975794106 hasConcept C2781413609 @default.
• W1975794106 hasConcept C2909463153 @default.
• W1975794106 hasConcept C526805850 @default.
• W1975794106 hasConcept C71924100 @default.
• W1975794106 hasConcept C90924648 @default.
• W1975794106 hasConceptScore W1975794106C121608353 @default.
• W1975794106 hasConceptScore W1975794106C126322002 @default.
• W1975794106 hasConceptScore W1975794106C141071460 @default.
• W1975794106 hasConceptScore W1975794106C143998085 @default.
• W1975794106 hasConceptScore W1975794106C2776694085 @default.
• W1975794106 hasConceptScore W1975794106C2777909004 @default.
• W1975794106 hasConceptScore W1975794106C2778424827 @default.
• W1975794106 hasConceptScore W1975794106C2778496288 @default.
• W1975794106 hasConceptScore W1975794106C2780456651 @default.
• W1975794106 hasConceptScore W1975794106C2780580376 @default.
• W1975794106 hasConceptScore W1975794106C2780962732 @default.
• W1975794106 hasConceptScore W1975794106C2781413609 @default.
• W1975794106 hasConceptScore W1975794106C2909463153 @default.
• W1975794106 hasConceptScore W1975794106C526805850 @default.
• W1975794106 hasConceptScore W1975794106C71924100 @default.
• W1975794106 hasConceptScore W1975794106C90924648 @default.
• W1975794106 hasIssue "1" @default.
• W1975794106 hasLocation W19757941061 @default.
• W1975794106 hasLocation W19757941062 @default.

• next